GLYATL1B

Across TCGA pan-cancer cohorts, GLYATL1B RNA is linked to patient survival in 20 of 34 cancer types, making it the most broadly survival-associated GLYATL1B data layer.

The strongest signal is observed in thyroid carcinoma (THCA), where higher GLYATL1B RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated GLYATL1B expression acts as an unfavorable survival marker, although some lineages such as OV and ESCA show a favorable association.

THCA, COAD, and PCPG are the cancer types where GLYATL1B RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THCA	DFS	Median	All	0.898	0.961	<.001	57	view →
COAD	DFS	Tertile	III,IV	0.137	0.530	<.001	52	view →
PCPG	OS	Tertile	All	0.063	0.970	<.001	36	view →
OV	DFS	Tertile	III,IV	0.211	0.127	.007	34	view →
KIRC	DFS	Quartile	IV	0.134	0.416	.005	33	view →
SKCM	DFS	Tertile	II,III,IV	0.459	0.611	.001	23	view →
UVM	DFS	Tertile	All	0.285	0.769	.010	18	view →
ESCA	DFS	Tertile	All	1.000	0.457	.014	9	view →
TGCT	OS	Median	All	0.915	1.000	.028	8	view →
CHOL	DFS	Median	IV	0.251	0.794	.010	6	view →
CESC	OS	Quartile	IV	0.801	0.218	.029	6	view →
UCEC	DFS	Tertile	II,III,IV	0.756	0.838	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 20 lineages.

GLYATL1B–THCA (DFS)

Open the THCA breakdown →